24 November 2020 - Expedited access to Oxlumo aims to support children and adults living with PH1 who face inevitable disease progression and irreversible kidney damage in the absence of new treatment options.
Alnylam Pharmaceuticals announced today a new framework for value-based agreements (VBAs) designed to help people with primary hyperoxaluria type 1 gain access to Oxlumo (lumasiran).
Alnylam is in active discussions with leading payers and has reached an agreement in principle with Express Scripts, Harvard Pilgrim, and Highmark to pursue VBAs for Oxlumo.